Self-Efficacy and Medication Adherence in Patients With Coronary Artery Disease: A Descriptive Study (SEMACAD)

April 24, 2025 updated by: Zeynal KİZİR, Hasan Kalyoncu University

Investigation of the Relationship Between Self-Efficacy and Adherence to Medication in Individuals With Coronary Artery Disease: A Descriptive and Correlational Study

This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.

This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.

Data collection tools include:

Descriptive Information Form to assess demographic and clinical characteristics,

The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),

Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).

The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.

Study Type

Observational

Enrollment (Estimated)

135

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: ZEYNAL KİZİR, PhD Student
  • Phone Number: +9005446445202 +9005446445202
  • Email: zkizir0234@gmail.com

Study Locations

  • Turkey
      • Adiyaman, Turkey, 02040
        • Recruiting
        • Adiyaman University Training and Research Hospital
        • Contact:
        • Principal Investigator:
          • Zeynal KİZİR, PhD Student
        • Sub-Investigator:
          • Aynur KOYUNCU, Assistant Professor
        • Sub-Investigator:
          • Ayla YAVA, Professor, PhD
        • Sub-Investigator:
          • Nuran TOSUN, Professor, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient/inpatient clinics at Adıyaman University Training and Research Hospital. All participants must be able to communicate in Turkish, have no diagnosed mental disorder, and voluntarily agree to participate in the study.

Description

Inclusion Criteria:

  • Being 18 years of age or older

Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago

Being followed

Being able to communicate in Turkish

Voluntarily agreeing to participate in the study

Having no diagnosed mental disorder

Exclusion Criteria:

  • Having a primary diagnosis other than Coronary Artery Disease

Being unable to complete the questionnaires due to mental health problems

Providing incomplete data or withdrawing from the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Coronary Artery Disease Patients
This cohort consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient or inpatient clinics. Patients included are those who volunteered to participate in the study, can communicate in Turkish, and do not have any mental disorders.
Other: No intervention
This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-efficacy score for chronic disease management
Time Frame: At the time of data collection (March 2025 - October 2025)
Self-efficacy levels of patients with coronary artery disease will be measured using the 6-Item Self-Efficacy Scale for Chronic Disease Management. Each item is rated from 1 to 10. The total score ranges from 6 to 60, and higher scores indicate better self-efficacy in chronic disease management.
At the time of data collection (March 2025 - October 2025)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication adherence score
Time Frame: At the time of data collection (March 2025 - October 2025)
Patients' adherence to their prescribed medication regimen will be assessed using the Medication Adherence Report Scale (MARS). The MARS scale ranges from 5 to 25, with higher scores indicating better medication adherence.
At the time of data collection (March 2025 - October 2025)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hasan Kalyoncu University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2025

Primary Completion (Estimated)

October 1, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

April 17, 2025

First Submitted That Met QC Criteria

April 17, 2025

First Posted (Actual)

April 24, 2025

Study Record Updates

Last Update Posted (Actual)

April 27, 2025

Last Update Submitted That Met QC Criteria

April 24, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HKU-KAH-2025-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This study does not plan to share individual participant data (IPD).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe